About Oleksandra Bystrova

This author has not yet filled in any details.
So far Oleksandra Bystrova has created 15 blog entries.

One Size Doesn’t Fit All: Why CRO Flexibility Matters More Than Ever

In today’s clinical development landscape, no two trials, or trial Sponsors, are exactly alike. Each organization brings its own needs, priorities, and operating models to the table. For this reason, outsourcing strategies for clinical trials can vary widely. Some Sponsors prefer to engage multiple specialized vendors, selecting only the services they need to complement their internal capabilities. Others opt for a single, full-service CRO to manage the entire trial, leaning on a unified partner for seamless execution.

By |2025-04-22T18:02:48+01:00March 25th, 2025|WEP Insights|

Early Access Programs (EAPs) in France: A Strategic Advantage for Pharma and Biotech Companies

Early Access Programs (EAPs) in France provide pharmaceutical and biotech companies with a valuable opportunity to offer patients innovative treatments before obtaining formal marketing authorization. Regulated by the French National Agency for the Safety of [...]

By |2025-03-06T16:44:24+00:00March 6th, 2025|Uncategorised|

The need for Harmonized Regulations in the Expanded/Early Access, Compassionate Use and Named Patient Use space

Expanded/Early Access (EA), Compassionate Use (CU) and Named Patient Use (NPU) are critical pathways for patients with serious or life-threatening conditions to obtain investigational treatments outside of clinical trials. While these programs offer hope for [...]

By |2025-02-11T12:53:50+00:00February 6th, 2025|WEP Insights|

Why Choosing a Small Contract Research Organization (CRO) Can Elevate Your Clinical Trials

In today’s fast-paced pharmaceutical landscape, selecting the right partner for your clinical trials is crucial. Here are some compelling benefits of opting for a small CRO: Personalized AttentionSmall CROs often provide tailored solutions and dedicated [...]

By |2025-01-29T14:21:15+00:00October 23rd, 2024|WEP Insights|